Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q2NKX8
UPID:
ERC6L_HUMAN
Alternative names:
ATP-dependent helicase ERCC6-like; PLK1-interacting checkpoint helicase; Tumor antigen BJ-HCC-15
Alternative UPACC:
Q2NKX8; Q8NCI1; Q96H93; Q9NXQ8
Background:
The DNA excision repair protein ERCC-6-like, also known as ATP-dependent helicase ERCC6-like, PLK1-interacting checkpoint helicase, and tumor antigen BJ-HCC-15, plays a crucial role in DNA repair mechanisms. It acts as a DNA helicase, a tension sensor associating with catenated DNA under tension until resolved during anaphase. Its ATP-dependent DNA translocase activity and ability to promote Holliday junction branch migration underscore its importance in maintaining genomic integrity.
Therapeutic significance:
Understanding the role of DNA excision repair protein ERCC-6-like could open doors to potential therapeutic strategies.